Perspective: Market structure and drug innovation

Health Affairs

Volumn 23, Issue 1, 2004, Pages 48-50

  Pammolli, Fabio ^a   Riccaboni, Massimo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

COST CONTROL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; ECONOMIC ASPECT; ECONOMIC EVALUATION; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE POLICY; ORGANIZATION; PRESCRIPTION; PRODUCTIVITY; PROFIT; PROSPECTIVE PRICING; REVIEW; ARTICLE; ECONOMICS; HEALTH CARE COST; LEGAL ASPECT; ORGANIZATION AND MANAGEMENT; RESEARCH; UNITED STATES;

COST CONTROL; DRUG INDUSTRY; HEALTH CARE SECTOR; RESEARCH; UNITED STATES;

EID: 4243189321     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.23.1.48     Document Type: Review

References (14)

1. J. DiMasi et al., "The Price of Innovation: New Estimates of Drug Development Costs," Journal of Health Economics 22, no. 2 (2003): 151-185.
2. PhRMA, Pharmaceutical Industry Profile, 2001 (Washington: PhRMA, 2001).
3. A. Gambardella, L. Orsenigo, and F. Pammolli, "Global Competitiveness in Pharmaceuticals: A European Perspective," Enterprise Paper no. I (Brussels: European Commission, 2001).
4. E.R. Berndt, "The U.S. Pharmaceutical Industry: Why Major Growth in Times of Cost Containment?" Health Affairs (Mar/Apr 2001): 100-114.
5. A. Gambardella, Science and Innovation: The U.S. Pharmaceutical Industry during the 1980s (Cambridge: Cambridge University Press, 1995); and L. Galambos and J. Sturchio, "The Pharmaceutical Industry in the Twentieth Century: A Reappraisal of the Sources of Innovation," History and Technology 13, no. 2 (1996): 83-100.
6. A. Gambardella, Science and Innovation: The U.S. Pharmaceutical Industry during the 1980s (Cambridge: Cambridge University Press, 1995); and L. Galambos and J. Sturchio, "The Pharmaceutical Industry in the Twentieth Century: A Reappraisal of the Sources of Innovation," History and Technology 13, no. 2 (1996): 83-100.
7. L. Orsenigo, F. Pammolli, and M. Riccaboni, "Technological Change and Network Dynamics: Lessons from the Pharmaceutical Industry," Research Policy 30, no. 3 (2001): 485-508; and F. Pammolli and M. Riccaboni, "Technological Regimes and the Growth of Networks: An Empirical Analysis," Small Business Economics 19, no. 2 (2001): 205-215.
8. L. Orsenigo, F. Pammolli, and M. Riccaboni, "Technological Change and Network Dynamics: Lessons from the Pharmaceutical Industry," Research Policy 30, no. 3 (2001): 485-508; and F. Pammolli and M. Riccaboni, "Technological Regimes and the Growth of Networks: An Empirical Analysis," Small Business Economics 19, no. 2 (2001): 205-215.
9. J. Owen Smith et al., "Comparison of U.S. and European University-Industry Relations in the Life Sciences," Management Science 48, no. 1 (2002): 24-43; and A. Arora, A. Fosfuri, and A. Gambardella, Markets for Technology: The Economics of Innovation and Corporate Strategy (Cambridge, Mass.: MIT Press, 2001).
10. J. Owen Smith et al., "Comparison of U.S. and European University-Industry Relations in the Life Sciences," Management Science 48, no. 1 (2002): 24-43; and A. Arora, A. Fosfuri, and A. Gambardella, Markets for Technology: The Economics of Innovation and Corporate Strategy (Cambridge, Mass.: MIT Press, 2001).
11. A. Arora et al., "The Nature and the Extent of the Market for Technology in Biopharmaceuticals," Cahiers de l'Innovation no. 7 (Paris: Centre Nationale de la Recherche Scientifique, April 2001).
12. J. Sutton, Technology and Market Structure: Theory and History (Cambridge, Mass.: MIT Press, 1998); and F. Pammolli et al., "Innovation and Corporate Growth in the Evolution of the Pharmaceutical Industry," International Journal of Industrial Organization 19, no. 3 (2001): 1161-1187.
13. J. Sutton, Technology and Market Structure: Theory and History (Cambridge, Mass.: MIT Press, 1998); and F. Pammolli et al., "Innovation and Corporate Growth in the Evolution of the Pharmaceutical Industry," International Journal of Industrial Organization 19, no. 3 (2001): 1161-1187.
14. D. Acemoglu and J. Linn, "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," NBER Working Paper 10038 (Cambridge: National Bureau of Economic Research, October 2003).